<DOC>
	<DOCNO>NCT01102972</DOCNO>
	<brief_summary>This study design compare efficacy safety simplify therapy regimen atazanavir ( ATV ) + ritonavir ( RTV ) + tenofovir/emtricitabine ( TDF/FTC ) regimen ATV + abacavir sulfate/lamivudine ( ABC/3TC ) without RTV virologically suppress , HIV-1 infect , HLA-B*5701 negative subject 48 week .</brief_summary>
	<brief_title>A Simplification Study Unboosted Reyataz With Epzicom ( ASSURE )</brief_title>
	<detailed_description>A prospective , randomize , multicenter , open-label study compare efficacy safety simplify regimen atazanavir ( ATV ) + ritonavir ( RTV ) + tenofovir/emtricitabine ( TDF/FTC ) ATV + abacavir sulfate/lamivudine ( ABC/3TC ) without RTV 48 week virologically suppress , HIV-1 infect , HLA-B*5701 negative subject . ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Subject adult ( great equal 18 year ) document HIV1 infection Subject male female nonchildbearing potential ( physiologically incapable become pregnant , premenarchal postmenopausal ) childbearing potential negative pregnancy test agree avoid pregnancy sexual abstinence utilization highly effective method birth control throughout study period Subject receive oncedaily regimen ATV ( 300mg ) + RTV ( 100mg ) + TDF/FTC ( 300mg/200mg ) least 6 month prior first day screen . ATV + RTV + TDF/FTC must subejct 's INITIAL regimen FIRST SECOND SWITCH regimen . If ATV + RTV + TDF/FTC subject 's first second switch regimen , subject may ONLY receive follow prior regimen : ) currently license nonnucleoside reverse transcriptase inhibitor ( NNRTI ) + TDF/FTC ZDV/3TC ; b ) RTVboosted PI TDF/FTC ZDV/3TC ; c ) alternative regimen list approval Sponsor . Subject virologically suppress ATV + RTV + TDF/FTC define HIV1 RNA &lt; /=75 copies/mL 2 consecutive timepoints , one Screening least 28 day prior Screening Subject evidence virologic failure Subject know HIV genotyping result indicate HIV virus contain follow resistance mutation reverse transcriptase include K65R , K70E , L74V , M184I/V Y115F , combination two thymidine analog mutation include M41L , D67N , K70R , K219Q E include change either L210 T215 ) , 3 follow HIV1 protease mutation associate atazanavir resistance : D30 , V32 , M36 , M46 , I47 , G48 , I50 , I54 , A71 , G73 , V77 , V82 , I84 , N88 , L90 Subject HLAB*5701 positive Subject hypersensitivity component study drug SUbject pregnant breastfeeding Subject enrol one investigational drug protocol within 30 day screen Subject active Center Disease Control Prevention ( CDC ) Category C disease , except cutaneous Kaposi 's sarcoma require systemic therapy trial Subject ongoing clinically relevant hepatitis screen and/or positive Hepatitis B ( + HbsAg ) Subject creatinine clearance &lt; 50 mL/min via CockcroftGault method Subject verify Grade 4 laboratory abnormality screen unless Investigator provide compel explanation ( e.g . elevate CPK due exercise ) laboratory result ( ) assent Sponsor Subject laboratory abnormality medical condition screening , , opinion investigator , would preclude subject 's participation study Subject immunization within 30 day prior first dose investigational product Subject exposure treatment immunomodulating agent ( systemic corticosteroid , interleukin , interferon ) receipt HIV1 immunotherapeutic vaccine within 90 day prior screen . Subjects use inhaled corticosteroid shortcourse systemic corticosteroid ( less equal 14 day ) eligible enrollment . Subject treatment radiation therapy cytotoxic chemotherapeutic agent within 90 day prior screen , anticipated need agent within study period Subject treatment within 30 day prior first dose investigational product anticipate need study medication interaction study medication , TDF , FTC , ABC , 3TC , ATV and/or RTV , describe current product labelling Subject treatment previous abacavircontaining regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
</DOC>